keyword
MENU ▼
Read by QxMD icon Read
search

egfr inhibitor skin

keyword
https://www.readbyqxmd.com/read/29777377/radiolabeled-f-ab-2-cetuximab-for-theranostic-purposes-in-colorectal-and-skin-tumor-bearing-mice-models
#1
P-S Bellaye, M Moreau, O Raguin, A Oudot, C Bernhard, J-M Vrigneaud, L Dumont, D Vandroux, F Denat, A Cochet, F Brunotte, B Collin
PURPOSE: This study aimed to investigate theranostic strategies in colorectal and skin cancer based on fragments of cetuximab, an anti-EGFR mAb, labeled with radionuclide with imaging and therapeutic properties, 111 In and 177 Lu, respectively. METHODS: We designed F(ab')2 -fragments of cetuximab radiolabeled with 111 In and 177 Lu. 111 In-F(ab')2 -cetuximab tumor targeting and biodistribution were evaluated by SPECT in BalbC nude mice bearing primary colorectal tumors...
May 17, 2018: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29771169/associations-between-skin-rash-treatment-outcome-and-single-nucleotide-polymorphisms-in-head-and-neck-cancer-patients-receiving-the-egfr-inhibitor-zalutumumab-results-from-the-dahanca-19-trial
#2
Line Brøndum, Jan Alsner, Brita Singers Sørensen, Christian Maare, Jørgen Johansen, Hanne Primdahl, Jan Folkvard Evensen, Claus Andrup Kristensen, Lisbeth Juhler Andersen, Jens Overgaard, Jesper Grau Eriksen
PURPOSE: To study the associations between development of moderate to severe skin rash, clinical outcome, and single nucleotide polymorphisms (SNPs) in candidate genes in head and neck cancer patients from the DAHANCA 19 trial receiving the EGFR-inhibitor zalutumumab concurrently with radiation treatment. MATERIAL AND METHODS: 310 patients were included from the zalutumumab-arm of the DAHANCA 19 study. Nine SNPs in the candidate genes EGFR, EGF, AREG, FCGR2A, FCGR3A, and CCND1 were successfully determined in 294 patients...
May 17, 2018: Acta Oncologica
https://www.readbyqxmd.com/read/29702285/brief-report-afatinib-and-cetuximab-in-four-patients-with-egfr-exon-20-insertion-positive-advanced-non-small-cell-lung-cancer
#3
Bianca van Veggel, Adrianus J de Langen, Sayed Hashemi, Kim Monkhorst, Daniëlle A M Heideman, Erik Thunnissen, Egbert F Smit
INTRODUCTION: Epidermal growth factor receptor (EGFR) exon 20 insertions comprise 4-9% of EGFR mutated non-small-cell lung cancer (NSCLC). Despite being an oncogenic driver, they are associated with primary resistance to EGFR tyrosine kinase inhibitors (TKIs). We hypothesized that dual EGFR blockade with afatinib, an irreversible EGFR TKI, and cetuximab, a monoclonal antibody against EGFR, could induce tumor responses. METHODS: Four patients with EGFR exon 20 insertion positive NSCLC were treated with afatinib 40 mg once daily and cetuximab 250-500 mg/m2 every two weeks...
April 24, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29626621/first-in-human-phase-i-study-of-ac0010-a-mutant-selective-egfr-inhibitor-in-non-small-cell-lung-cancer-safety-efficacy-and-potential-mechanism-of-resistance
#4
Yuxiang Ma, Xin Zheng, Hongyun Zhao, Wenfeng Fang, Yang Zhang, Jieying Ge, Lu Wang, Weicong Wang, Ji Jiang, Shaokun Chuai, Zhou Zhang, Wanhong Xu, Xiao Xu, Pei Hu, Li Zhang
INTRODUCTION: AC0010 is a mutation-selective, third-generation EGFR tyrosine kinase inhibitor (TKI). This first-in-human phase I trial determine the maximum tolerated dose (MTD), recommended phase II dose (RP2D), schedule, safety, pharmacokinetics, pharmacodynamics, and antitumor activity of AC0010 in patients with advanced or recurrent NSCLC and acquired resistance to the first-generation EGFR-TKI. METHODS: Patients received escalating daily doses of AC0010 (50 to 600 mg) throughout 28-day cycles...
April 4, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29590083/efficacy-of-gefitinib-and-radiotherapy-combination-in-indonesian-patients-with-lung-adenocarcinoma
#5
Elisna Syahruddin, Aida Lufti Huswatun, Ari Prabowo, Jamal Zaini, Fariz Nurwidya, Achmad Hudoyo, Anwar Jusuf
INTRODUCTION: Combinations of gefitinib and radiotherapy have been observed to have synergistic and anti-proliferative effects on lung cancer in vitro. In the clinical setting, patients who presented with respiratory difficulties such as superior vena cava syndrome (SVCS), radiotherapy should be given immediately to address the emergency while waiting for the results of epidermal growth factor receptor (EGFR) mutation test. However, there has been no study that described the role of radiotherapy in Indonesian patients with EGFR-mutant lung adenocarcinoma...
March 1, 2018: Romanian Journal of Internal Medicine, Revue Roumaine de Médecine Interne
https://www.readbyqxmd.com/read/29577978/thrombin-promotes-pai-1-expression-and-migration-in-keratinocytes-via-erk-dependent-smad-linker-region-phosphorylation
#6
Nirali Talati, Danielle Kamato, Terrence J Piva, Peter Little, Narin Osman
Keratinocyte proliferation and migration is essential during re-epithelialisation for the restoration of the epithelial barrier during skin wound healing. Numerous growth factors are involved in the stimulation of keratinocyte proliferation and migration. The signalling pathways that drive these processes during wound healing are not well defined. This study investigated thrombin-mediated signalling in keratinocytes. The thrombin receptor, protease-activated receptor 1 (PAR-1) is a seven transmembrane G-protein coupled receptor that is known to transactivate the epidermal growth factor receptor (EGFR)...
March 22, 2018: Cellular Signalling
https://www.readbyqxmd.com/read/29576427/dermatologic-toxicity-occurring-during-anti-egfr-monoclonal-inhibitor-therapy-in-patients-with-metastatic-colorectal-cancer-a-systematic-review
#7
REVIEW
Mario E Lacouture, Milan Anadkat, Aminah Jatoi, Tamer Garawin, Chet Bohac, Edith Mitchell
Monoclonal antibody inhibitors of the epidermal growth factor receptor (EGFR) have been shown to improve outcomes for patients with metastatic colorectal cancer (mCRC) without RAS gene mutations. However, treatment with anti-EGFR agents can be associated with toxicities of the skin, nails, hair, and eyes. Because these dermatologic toxicities can result in treatment discontinuation and affect patient quality of life, their management is an important focus when administering anti-EGFR monoclonal antibodies. The present systematic review describes the current data reporting the nature and incidence of, and management and treatment options for, dermatologic toxicities occurring during anti-EGFR treatment of mCRC...
December 13, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/29549700/cutaneous-toxicities-of-epidermal-growth-factor-receptor-inhibitors-a-prospective-study-in-60-asian-patients
#8
Leena Chularojanamontri, Papapit Tuchinda, Chayanee Likitwattananurak, Kamolwan Pongparit, Chuda Rujitharanawong, Suthinee Ithimakin, Kanokvalai Kulthanan
BACKGROUND: Several prospective studies have been conducted in epidermal growth factor receptor (EGFR) inhibitor-related cutaneous reactions in Caucasian patients, but prospective studies in Asian populations are scarce. OBJECTIVE: To investigate the cutaneous side effects of EGFR inhibitors in Asian cancer patients and to assess tumor response to dermatologic manifestations. METHODS: Sixty patients with lung or colorectal cancer who were receiving EGFR inhibitors were prospectively followed for at least one year by oncologists and dermatologists...
March 12, 2018: Asian Pacific Journal of Allergy and Immunology
https://www.readbyqxmd.com/read/29526950/pulmonary-adenocarcinoma-harboring-both-an-egfr-mutation-and-alk-rearrangement-presenting-a-stable-disease-to-erlotinib-and-a-partial-response-to-alectinib-a-case-report
#9
Akira Yokoyama, Atsuhisa Tamura, Kazuko Miyakawa, Kei Kusaka, Masahiro Shimada, Takashi Hirose, Hirotoshi Matsui, Masashi Kitani, Akira Hebisawa, Ken Ohta
A 63-year-old woman with pulmonary adenocarcinoma (stage IIIB) that was positive for an epidermal growth factor receptor (EGFR) mutation and an anaplastic lymphoma kinase (ALK) rearrangement was treated with erlotinib as the first-line treatment, resulting in a stable disease. Due to skin rashes, fatigue and anorexia, erlotinib was suspended on erlotinib day 44. Alectinib was administered as the second-line treatment, exhibiting a partial response. On alectinib day 56, drug-induced lung injury forced suspension of alectinib, which was cured with corticosteroid therapy...
March 9, 2018: Internal Medicine
https://www.readbyqxmd.com/read/29507555/the-incidence-and-management-of-cutaneous-adverse-events-of-the-epidermal-growth-factor-receptor-inhibitors
#10
REVIEW
Witold Owczarek, Monika Słowińska, Aleksandra Lesiak, Magdalena Ciążyńska, Aldona Maciąg, Elwira Paluchowska, Luiza Marek-Józefowicz, Rafał Czajkowski
Overexpression of the epidermal growth factor receptor (EGFR) is found in many cancers, including those of the head and neck area, non-small-cell lung cancer, and colorectal, cervical, prostate, breast, ovary, stomach, and pancreatic cancer. The EGFR inhibitors are used at present in the treatment of such cancers. Skin lesions that develop during and after cancer treatment may be due to specific cytostatics, molecular-targeted drugs, radiation therapy, complementary therapy, or the cancer itself, and hence knowledge is essential to distinguish between them...
October 2017: Postȩpy Dermatologii i Alergologii
https://www.readbyqxmd.com/read/29506988/phase-ii-study-of-the-dual-egfr-her3-inhibitor-duligotuzumab-mehd7945a-versus-cetuximab-in-combination-with-folfiri-in-second-line-ras-wild-type-metastatic-colorectal-cancer
#11
Andrew G Hill, Michael P Findlay, Matthew E Burge, Christopher Jackson, Pilar Garcia Alfonso, Leslie Samuel, Vinod Ganju, Meinolf Karthaus, Alessio Amatu, Mark Jeffery, Maria Di Bartolomeo, John Bridgewater, Andrew L Coveler, Manuel Hidalgo, Amy V Kapp, Roxana I Sufan, Bruce B McCall, William D Hanley, Elicia M Penuel, Andrea Pirzkall, Josep Tabernero
Purpose: Duligotuzumab is a dual-action antibody directed against EGFR and HER3. Experimental Design: Metastatic colorectal cancer (mCRC) patients with KRAS ex2 wild-type received duligotuzumab or cetuximab and FOLFIRI until progression or intolerable toxicity. Mandatory tumor samples underwent mutation and biomarker analysis. Efficacy analysis was conducted in patients with RAS exon 2/3 wild-type tumors. Results: Of 134 randomly assigned patients, 98 had RAS ex2/3 wild-type. Duligotuzumab provided no progression-free survival (PFS) or overall survival (OS) benefit compared with cetuximab, although there was a trend for a lower objective response rate (ORR) in the duligotuzumab arm...
May 15, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29491117/skin-rash-can-be-a-useful-marker-for-afatinib-efficacy
#12
Shingo Nasu, Hidekazu Suzuki, Takayuki Shiroyama, Ayako Tanaka, Kaori Iwata, Noriko Ryota, Yuki Ueda, S O Takata, Kentaro Masuhiro, Satomu Morita, Naoko Morishita, Norio Okamoto, Tomonori Hirashima
BACKGROUND/AIM: Although afatinib has a strong efficacy, it can be toxic; hence, we aimed to determine markers of response to afatinib in order to assess prognosis. PATIENTS AND METHODS: Information on clinical background, therapeutic effects, and adverse events was collected retrospectively at one Institution from patients treated with afatinib as initial epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI). We examined the relationship between different adverse events and their effects on prognosis...
March 2018: Anticancer Research
https://www.readbyqxmd.com/read/29485795/drug-induced-photosensitivity-a-continuing-diagnostic-challenge
#13
REVIEW
Liborija Lugović-Mihić, Tomislav Duvančić, Iva Ferček, Petra Vuković, Iva Japundžić, Diana Ćesić
When taking different drugs, their possible side effects on the skin should be considered, including skin reactions connected to photosensitivity. This photosensitivity caused by drugs can appear as phototoxic reactions (which occur more often) or photoallergic reactions (which occur less often and include allergic mechanisms). The following drugs stand out as medications with a high photosensitivity potential: nonsteroidal anti-inflammatory drugs (NSAIDs), cardiovascular drugs (such as amiodarone), phenothiazines (especially chlorpromazine), retinoids, antibiotics (sulfonamides, tetracyclines, especially demeclocycline and quinolones), etc...
June 2017: Acta Clinica Croatica
https://www.readbyqxmd.com/read/29462253/overview-of-current-systemic-management-of-egfr-mutant-nsclc
#14
W-H Hsu, J C-H Yang, T S Mok, H H Loong
Front-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy is the standard of care for lung cancer patients with sensitising EGFR mutations (exon 19 deletion or L858R mutation). Several phase III studies have demonstrated the superiority of gefitinib, erlotinib (first generation of TKIs) or afatinib (second generation) to chemotherapy in progression-free survival and response rates. Drug-related toxicities, such as diarrhoea, acneiform skin rash, mucositis, and paronychia, are frequently encountered in patients who receive EGFR TKIs...
January 1, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29450147/lemongrass-cymbopogon-flexuosus-essential-oil-demonstrated-anti-inflammatory-effect-in-pre-inflamed-human-dermal-fibroblasts
#15
Xuesheng Han, Tory L Parker
Lemongrass ( Cymbopogon flexuosus ) essential oil (LEO), which has citral as its main component, has exhibited anti-inflammatory effect in both animal and human cells. In this study, we evaluated the anti-inflammatory activity of a commercially available LEO in pre-inflamed human dermal fibroblasts. We first studied the impact of LEO on 17 protein biomarkers that are critically associated with inflammation and tissue remodeling. LEO significantly inhibited production of the inflammatory biomarkers vascular cell adhesion molecule 1 (VCAM-1), interferon gamma-induced protein 10 (IP-10), interferon-inducible T-cell alpha chemoattractant (I-TAC), and monokine induced by gamma interferon (MIG); decreased levels of the tissue remodeling biomarkers collagen-I and III, epidermal growth factor receptor (EGFR), and plasminogen activator inhibitor (PAI-1); and inhibited the immunomodulatory biomarker macrophage colony-stimulating factor (M-CSF)...
June 2017: Biochimie Open
https://www.readbyqxmd.com/read/29450144/anti-inflammatory-tissue-remodeling-immunomodulatory-and-anticancer-activities-of-oregano-origanum-vulgare-essential-oil-in-a-human-skin-disease-model
#16
Xuesheng Han, Tory L Parker
The use of oregano ( Origanum vulgare ) essential oil (OEO) has become popular in skin care products. However, scientific research regarding its effects on human skin cells is scarce. In this study, we investigated the biological activity of a commercially available OEO, which is high in carvacrol content, in a human skin cell disease model. OEO induced marked antiproliferative effects and significantly inhibited several inflammatory biomarkers, including monocyte chemoattractant protein 1 (MCP-1), vascular cell adhesion molecule 1 (VCAM-1), intracellular cell adhesion molecule 1 (ICAM-1), interferon gamma-induced protein 10 (IP-10), interferon-inducible T-cell alpha chemoattractant (I-TAC), and monokine induced by gamma interferon (MIG)...
June 2017: Biochimie Open
https://www.readbyqxmd.com/read/29426804/escmid-study-group-for-infections-in-compromised-hosts-esgich-consensus-document-on-the-safety-of-targeted-and-biological-therapies-an-infectious-diseases-perspective-cell-surface-receptors-and-associated-signaling-pathways
#17
REVIEW
J Aguilar-Company, M Fernández-Ruiz, R García-Campelo, A C Garrido-Castro, I Ruiz-Camps
BACKGROUND: The present review is part of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biologic therapies. AIMS: To review, from an infectious diseases perspective, the safety profile of therapies targeting cell surface receptors and associated signaling pathways among cancer patients and to suggest preventive recommendations...
February 7, 2018: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/29402243/treatment-decisions-clinical-outcomes-and-pharmacoeconomics-in-the-treatment-of-patients-with-egfr-mutated-stage-iii-iv-nsclc-in-germany-an-observational-study
#18
Wolfgang Schuette, Peter Schirmacher, Wilfried E E Eberhardt, Manfred Dietel, Ute Zirrgiebel, Lars Muehlenhoff, Michael Thomas
BACKGROUND: We evaluated treatment decisions and outcomes in a cohort of predominately Caucasian patients with EGFR mutation-positive (EGFR Mut+) non-small-cell lung cancer (NSCLC). METHODS: REASON (NCT00997230) was a non-interventional study in German patients with stage IIIB/IV NSCLC. Secondary endpoints for EGFR Mut + NSCLC included progression-free survival (PFS), overall survival (OS), adverse event (AE) management, and pharmacoeconomic outcomes. RESULTS: Among 334 patients with EGFR Mut + NSCLC, tyrosine kinase inhibitors (TKIs) were the most common first-line therapy (56...
February 5, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29387237/bioinformatics-analysis-of-gene-expression-alterations-conferring-drug-resistance-in-tumor-samples-from-melanoma-patients-with-egfr-activating-braf-mutations
#19
Yang Yu, Xueer Wang, Qinglin Li, Min Zhang, Pengcheng Xu, Yinghua Chen, Yuan Yan, Lin Zhang
Melanoma is a highly malignant tumor of the skin melanocytes. Patients with this cancer have a high frequency (~50%) of oncogenic BRAF mutations, particularly BRAF V600E. Treatments for melanoma often target BRAF mutations or involve mitogen-activated protein kinase kinase/extracellular signal-regulated kinase inhibitors. A major challenge in melanoma treatment is resistance to BRAF inhibitor treatment, which may be enhanced by the BRAF mutation itself and/or epidermal growth factor receptor (EGFR) activation, leading to poor prognosis...
January 2018: Oncology Letters
https://www.readbyqxmd.com/read/29377278/hypertrichosis-of-the-pinnae-in-a-patient-using-panitumumab
#20
LETTER
C Baykal, G Babuna Kobaner
No abstract text is available yet for this article.
January 29, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
keyword
keyword
102815
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"